This is a non-core endpoint: only basic statistics are computed.
Melanocytic naevi of other and unspecified parts of face (controls excluding all cancers)
CD2_BENIGN_MELANOCYTIC_FACE_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D22.3&
Hospital discharge: ICD-9
2163A
Cause of death: ICD-10
D22.3&
Cause of death: ICD-9
2163A
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
1574
CD2_BENIGN_MELANOCYTIC_FACE_EXALLC
Control definitions
Control exclude
C3_CANCER
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D22
Name in latin
Naevus melanocyticus (cutis) faciei
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Melanocytic naevi of other and unspecified parts of face (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Melanocytic naevi of other and unspecified parts of face
- Melanocytic naevi
- Melanocytic naevi (controls excluding all cancers)
- Benign neoplasms (controls excluding all cancers)
- Benign neoplasms
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1574 | 1098 | 476 |
| Unadjusted prevalence (%) | 0.42 | 0.52 | 0.29 |
| Mean age at first event (years) | 48.56 | 46.16 | 54.11 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_BENIGN_MELANOCYTIC_FACE_EXALLC – Melanocytic naevi of other and unspecified parts of face (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Melanocytic naevi of other and unspecified parts of face (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.